• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Resources for Maviret and Hepatitis C Virus (HCV)

      As part of our commitment to healthcare professionals working in HCV, we have provided downloadable and viewable resources to support you, your team, and your patients.

       

      For healthcare professionals

      Maviret Information Leaflet

      This digital piece, for healthcare professionals only, summarises key efficacy, dosing and safety information for treatment-naïve patients.

      “Streamlining the hepatitis C test-and-treat pathway in a remand prison: real-world experience from HMP Swansea”  – Hints and Tips

      James Plant is a Blood Borne Virus Specialist Nurse working in HMP Swansea, a remand prison with a known high prevalence of PWID and people susceptible to infection with blood borne viruses, including hepatitis C.

      Challenges: the average length of stay in HMP Swansea is 8–12 weeks, making it challenging to diagnose hepatitis C and complete treatment in this incarcerated population prior to release. Furthermore, upon release into the community, clients are often lost to follow-up and can become hard to reach.

      Aim: to streamline the test-and-treat pathway, allowing hepatitis C to be diagnosed and treatment to be commenced and completed during the period of custody.

      Results: through collaboration between multidisciplinary teams and engagement of peers, HMP Swansea implemented a successful model of care involving point-of-care testing, opt-out screening and an accessible supply of medication.

      Here, James Plant shares his key learnings of the process to support other prison settings in implementing HMP Swansea’s new model of care.

      Professor Graham Foster Talking Head Video and Infographic – “Time is of the essence – the drive to HCV elimination”

      In this video and supporting infographic, Professor Foster reinforces the urgent need for Hepatitis C Virus (HCV) elimination and offers practical tips on how this could be achieved across the devolved nations.

      Dr Andrew Radley Talking Head Video and Infographic – “The role of community pharmacy antibody testing services in the elimination of hepatitis C”

      This video and supporting infographic aim to share best practice and key learnings from NHS Tayside, a health board in Scotland where hepatitis C elimination has been achieved. Here, Dr Radley outlines his top tips for establishing antibody testing services within community pharmacies to support hepatitis C elimination.

      Professor Ashley Brown Talking Head Videos and Infographics “The role of antenatal testing in elimination of hepatitis C”

      This video and supporting infographic draws on Professor Brown’s clinical experience in London, where he highlights the importance of antenatal testing for hepatitis C elimination, including specific populations to test in antenatal clinics.

      “Steps towards achieving elimination of hepatitis C in a prison setting”

      This video and supporting infographic aim to provide practical advice on how hepatitis C elimination could be achieved in prison settings. Professor Brown discusses steps to shorten the treatment pathway for these patients through rapid screening, testing and treatment and the benefit of peer support.

      “Hepatitis C test and treat: learnings from COVID-19”

      In this talking head and supporting infographic, Professor Brown outlines how clinical practice has adapted during the COVID-19 pandemic. He highlights the positive changes made and those which could be applied moving forwards to support hepatitis C elimination.

      Maviret Toolkit to Encourage And Motivate (TEAM)

      This resource is designed to help motivate and engage your team during face-to-face or virtual meetings.

      Part 1 includes ice-breaker activities, mood barometers and motivational quotes that can be downloaded and incorporated into your meeting slides.

      Part 2 offers further valuable tools to support your face-to-face or virtual meetings. Useful hints and tips on how to get the most out of your virtual meeting platform are also available in this toolkit.

      HCP resources for your patients

      Maviret Patient Guide (Digital version)

      To support your patients who are on Maviret, this guide provides information on Maviret such as dosing, potential side-effects and FAQs.

      The information in this booklet does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.

      Maviret Patient Guide (Print Version)

      For patients who prefer not to receive information digitally, this printed booklet contains all of the content of the Maviret Patient Guide (see above).

      The information in this booklet does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.

      To receive this document by post, submit your details on the Contact Us and tick Maviret Patient Guide.

      Maviret Patient Leaflet (Credit Card Sized)

      This leaflet, which can be folded to the size of a credit card for easier portability, contains a treatment tracker for patients to fill out, to help them keep track of their Maviret treatment over an 8, 12, or 16-week course. It also contains information on Maviret dosing, potential side-effects, and HCV support groups.

      The information in this booklet does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.

      To receive this document by post, submit your details on the Contact Us page and tick Maviret Patient Leaflet.

      Hep C Poster (Print version)

      This A4 poster provides patients with information on hepatitis C treatments with the aim of encouraging potential patients to get tested for hepatitis C.

      To receive this poster via post, submit your details on the
      Contact Us page and tick Hep C poster.

      *Cure = sustained virologic response (SVR12), defined as HCV RNA less than lower limit of quantification at 12 weeks after the end of treatment and was the primary endpoint in all the studies.1

      Refers to GT 1–6, excluding decompensated cirrhotic patients and liver or kidney transplant recipients. MAVIRET is not indicated in decompensated cirrhosis. The recommended duration of MAVIRET is 12 weeks in liver or kidney transplant recipients, with or without cirrhosis.

      GT = Genotype; HCV = Hepatitis C Virus; SVR = Sustained virologic response.

      PWID = People Who Inject Drugs


      I want to receive more information via a product specialist 


      References

      1. Maviret Summary of Product Characteristics. AbbVie Ltd. Available at: www.medicines.org.uk

       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      UK-MAVI-210068. Date of preparation: February 2022